Trial Protocol ID USOR 21541_DS1062-A-U304_TROPION-Lung08

Trial Description

A Randomized, Open-Label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs. Pembrolizumab
Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-Lung08)

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Vinni Juneja, M.D.

Disease Types


  • Daiichi Sankyo NCT ID

  • NCT05215340